Neuroprotective effects of ursodeoxycholic acid in Parkinson's disease and Alzheimer's disease
Neuroprotection · 2026-06 · 4 (2) · 111-130
DOI: 10.1002/nep3.70039 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Neuroprotection, online erschienen am 18.05.2026. Verfasst von Ashley En Yi Chong und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Applied Biomedical Sciences and Biotechnology, School of Health Sciences IMU University Kuala Lumpur Malaysia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 195 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.
Themen: Demenz
Abstract (Originalsprache)
Neurodegenerative diseases (NDDs) including Parkinson's disease (PD) and Alzheimer's disease (AD), are progressive disorders characterised by shared pathological features, including mitochondrial dysfunction, oxidative stress, apoptosis, neuroinflammation, neurotoxic protein buildup, and impaired protein clearance. Current treatments can only relieve disease symptoms but cannot delay the disease progression. Ursodeoxycholic acid (UDCA), a hydrophilic bile acid traditionally used in hepatology, has recently gained attention for its neuroprotective properties. This review critically evaluates UDCA's mechanisms of action, including the restoration of mitochondrial function, inhibition of apoptosis, reduction of oxidative stress and neuroinflammation, and enhancement of autophagy in both PD and AD models. In vitro and in vivo studies demonstrate UDCA's ability to preserve neuronal integrity, improve motor and cognitive outcomes, and reduce toxic protein aggregates. Although early‐phase clinical trials, such as the UDCA for Parkinson's (UP) study in PD, show promising mitochondrial benefits and safety, clinical evidence in AD remains limited. Future directions emphasise the need for large‐scale trials, personalised medicine, improved central nervous system (CNS) delivery strategies, or dietary interventions to modulate UDCA production from the gut microbiome. While not a first‐line treatment, UDCA represents a compelling mitochondrial stabiliser with disease‐modifying potential in NDDs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Applied Biomedical Sciences and Biotechnology, School of Health Sciences IMU University Kuala Lumpur Malaysia.
- Department of Anatomy and Neuroscience University College Cork Cork Ireland.
- APC Microbiome Ireland University College Cork Cork Ireland.
ORCID-Profile: Andrew Octavian Sasmita, Anna Pick Kiong Ling
Förderung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Chong, A. E. Y., Sasmita, A. O., Koh, R. Y., & Ling, A. P. K. (2026). Neuroprotective effects of ursodeoxycholic acid in Parkinson's disease and Alzheimer's disease. Neuroprotection, 4(2), 111-130. https://doi.org/10.1002/nep3.70039
Vancouver
Chong AEY, Sasmita AO, Koh RY, Ling APK. Neuroprotective effects of ursodeoxycholic acid in Parkinson's disease and Alzheimer's disease. Neuroprotection. 2026;4(2):111-130. doi:10.1002/nep3.70039
BibTeX
@article{Chong2026,
author = {Chong, Ashley En Yi and Sasmita, Andrew Octavian and Koh, Rhun Yian and Ling, Anna Pick Kiong},
title = {Neuroprotective effects of ursodeoxycholic acid in Parkinson's disease and Alzheimer's disease},
journal = {Neuroprotection},
year = {2026},
volume = {4},
number = {2},
pages = {111--130},
doi = {10.1002/nep3.70039}
}
EUVIMED